Answers are grounded in this paper and cite their sources.
Background Tuberculosis (TB) remains a leading infectious cause of death, with drug-resistant TB (DR-TB) challenging disease control. Brazil has a high TB burden, and Rio Grande do Sul state reports persistently high incidence and drug-resistance rates. The drivers shaping the regional DR-TB burden remain poorly characterised. Methods We conducted genomic surveillance of confirmed DR-TB cases in Rio Grande do Sul, Brazil, from January 2023 to September 2024. Clinical isolates underwent genotypic (gDST) and phenotypic drug susceptibility testing (pDST) and whole-genome sequencing (WGS). We analyzed 33 newly sequenced genomes and 267 historical Mycobacterium tuberculosis genomes collected in 2011-2019 to characterize resistance, transmission, and spatiotemporal patterns and estimate the contributions of transmitted and acquired rifampicin resistance. Findings Molecular testing detected rifampicin resistance missed by pDST, including borderline rpoB mutations in 18.2% and emerging resistance-associated variants in 3% of the 33 analyzed isolates. Conversely, pDST detected baseline bedaquiline resistance missed by WGS in one newly diagnosed case. Among 300 genomes, 181 (60.3%) clustered into 32 genomic clusters at a 5-SNP threshold, including 12 with long-term circulation and several spanning prisons and communities. Sublineage frequencies remained stable over time, whereas we observed marked geographic structuring and localized clonal expansion. Among 178 rifampicin-resistant isolates, transmission accounted for an estimated 79.2-88.2% of resistance, corresponding to 11.8-20.8% of cases arising through de novo acquisition during treatment. Interpretation Our findings identify active transmission as the main driver of rifampicin-resistant TB in Rio Grande do Sul, with long-term transmission chains extending across both incarcerated and community settings. These results underscore the urgent need to strengthen timely TB case detection and resistance testing, enhance contact investigations, and implement targeted interventions aiming to interrupt persistent transmission chains.
No takes yet. Share an insight, caveat, or question.
Soares et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: